Bharat Immunologicals and Biologicals Corporation

BIBCOL was incorporated on 10 March 1989 as a public sector undertaking under the Companies Act, 1956. The Government of India created the company through the Department of Biotechnology, then operating within the Ministry of Science and Technology, to establish domestic capacity for oral polio vaccine production. Its formation was tied directly to India’s national immunisation priorities and the wider campaign to eliminate poliomyelitis. The company’s main manufacturing base was established at Bulandshahr in Uttar Pradesh. Its central product was trivalent oral polio vaccine using attenuated Sabin strains representing poliovirus types 1, 2 and 3. BIBCOL was reported to have the capacity to formulate more than 12.5 crore doses. Its institutional role meant that sales were primarily connected with public procurement rather than consumer-facing retail branding. During the early 2000s, the company received supply orders from India’s Ministry of Health and Family Welfare and UNICEF. In 1999, BIBCOL obtained WHO Good Manufacturing Practices certification for its production facilities. The certification represented an important quality and regulatory milestone, particularly for a state-owned manufacturer supplying vaccines intended for large-scale immunisation campaigns. The company subsequently broadened its public-health portfolio beyond oral polio vaccine. Products described in reference material include a diarrhea-management kit combining zinc tablets with oral rehydration salts, BIBZinC-20 mg zinc dispersible tablets, and iron-folic-acid tablets used in the management of iron-deficiency anemia. The zinc product was developed in line with WHO recommendations and used technology transferred from Nutriset through the Department of Biotechnology and the Ministry of Science and Technology. The product was described as a scored, vanilla-flavored dispersible tablet containing 20 mg of elemental zinc. These products reflected BIBCOL’s broader public-health orientation: supplying affordable interventions for childhood diarrhea, micronutrient deficiency, and anemia alongside its vaccine activities. During the COVID-19 pandemic, the Government of India selected BIBCOL as one of several public-sector entities intended to help expand manufacture of Covaxin, a vaccine developed by Bharat Biotech. BIBCOL began upgrading its Bulandshahr facilities, including biosafety infrastructure needed for the proposed vaccine-production role. The available account does not provide enough information to determine the final production volume or the duration of Covaxin manufacturing at the site. BIBCOL’s administrative control remained with the Department of Biotechnology. The company reported aggregate revenue of ₹30.5 crore in fiscal 2006. A later inflation-adjusted presentation characterized that amount as approximately ₹98 crore in 2023 terms, or roughly US$10 million, but the figure is historical and should not be interpreted as current revenue. In 2024, the Government of India approved BIBCOL for closure. The available source does not state whether the closure had been legally completed, so the company’s final operating status remains uncertain.

• 2024

  Closure approved

  [1]Bharat Immunologicals and Biologicals Corporationen.wikipedia.org

  The Government of India approved BIBCOL for closure. The available material does not establish when the closure process was completed.

• 2021

  Selected for planned Covaxin manufacturing expansion

  [1]Bharat Immunologicals and Biologicals Corporationen.wikipedia.org

  BIBCOL was selected among public-sector manufacturers considered for expanded Covaxin production during the COVID-19 pandemic and began facility and biosafety upgrades.

• 2006

  Reported fiscal revenue

  [1]Bharat Immunologicals and Biologicals Corporationen.wikipedia.org

  BIBCOL reported aggregate revenue of ₹30.5 crore for fiscal 2006, a historical figure rather than a current financial measure.

• 1999

  WHO Good Manufacturing Practices certification

  [1]Bharat Immunologicals and Biologicals Corporationen.wikipedia.org

  BIBCOL obtained WHO Good Manufacturing Practices certification for its production facilities.

• 1989

  BIBCOL incorporated

  [1]Bharat Immunologicals and Biologicals Corporationen.wikipedia.org

  Bharat Immunologicals and Biologicals Corporation was incorporated on 10 March 1989 as a Government of India public sector undertaking to manufacture oral polio vaccine.

A government-owned Indian public-health manufacturer focused on vaccines, immunisation support, and essential nutritional or therapeutic products for national health programs.

• Vaccine

  Oral Polio Vaccine

  BIBCOL’s principal historical product was a live, trivalent oral polio vaccine containing attenuated Sabin strains of poliovirus types 1, 2 and 3. The vaccine was prepared using primary monkey-kidney-cell culture and was intended primarily for India’s national immunisation program and related public-health procurement. BIBCOL was reported to have capacity to formulate more than 12.5 crore doses.

• Public-health therapeutic kit

  Diarrhea Management Kit

  A public-health kit combining zinc tablets with oral rehydration salts. It was intended to support the management of diarrhea among young children, addressing both fluid loss and the recognized role of zinc supplementation in diarrhea treatment. The available material does not specify packaging, distribution volumes, or current availability.

• Zinc supplement

  BIBZinC-20 mg

  A dispersible zinc tablet containing 20 mg of elemental zinc. The tablet was described as scored, sweetened, and vanilla-flavored to improve acceptability, particularly in child-health applications. Its development followed WHO-aligned recommendations and involved technology transfer from Nutriset through India’s Department of Biotechnology and Ministry of Science and Technology.

• Iron and folic acid supplement

  IFA Tablets

  Iron-folic-acid tablets intended to address iron-deficiency anemia. The product formed part of BIBCOL’s wider public-health portfolio beyond vaccines, targeting a common nutritional deficiency in developing-country health systems. The available material does not provide formulation details, launch timing, or present distribution status.

• COVID-19 vaccine manufacturing · 2021

  Covaxin manufacturing program

  BIBCOL was selected during the COVID-19 pandemic as a public-sector manufacturer intended to help expand production of Covaxin, a vaccine developed by Bharat Biotech. The proposed role required upgrades to the Bulandshahr facility, including biosafety infrastructure. The available source does not establish the eventual production scale or whether the program reached sustained commercial output.

• 1989National oral-polio-vaccine support

  India

  BIBCOL was created to supply oral polio vaccine for India’s national immunisation program and to support the country’s polio-eradication effort.

  Outcome. The company became a public-sector supplier of oral polio vaccine and built its core identity around national public-health manufacturing.

  Source

• 2024

  Approve corporate closureOther

  Background

  After decades as a government-owned vaccine and public-health manufacturer, the Government of India reviewed the company’s future.

  Action taken

  The government approved BIBCOL for closure.

  Aftermath

  The available source does not specify whether the legal winding-up process was completed or how the company’s assets and manufacturing capabilities were handled.

  Source

• 2021

  Expand into planned Covaxin manufacturingStrategy

  Background

  The COVID-19 pandemic created urgent demand for additional domestic vaccine-manufacturing capacity in India.

  Action taken

  The Government of India selected BIBCOL among public-sector manufacturers for planned Covaxin production and supported upgrades to its Bulandshahr facility, including biosafety infrastructure.

  Aftermath

  The available material confirms facility-upgrade activity but does not provide enough evidence to quantify final production or commercial impact.

  Source

1. 1Bharat Immunologicals and Biologicals Corporationen.wikipedia.org